• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A negative selection methodology using a microfluidic platform for the isolation and enumeration of circulating tumor cells.一种使用微流控平台进行循环肿瘤细胞分离和计数的负选择方法。
Methods. 2013 Dec 1;64(2):137-43. doi: 10.1016/j.ymeth.2013.05.027. Epub 2013 Jun 24.
2
Nanoroughened adhesion-based capture of circulating tumor cells with heterogeneous expression and metastatic characteristics.基于纳米粗糙化粘附捕获具有异质性表达和转移特征的循环肿瘤细胞。
BMC Cancer. 2016 Aug 8;16:614. doi: 10.1186/s12885-016-2638-x.
3
Circulating tumor cells: clinically relevant molecular access based on a novel CTC flow cell.循环肿瘤细胞:基于新型循环肿瘤细胞流动池的临床相关分子检测方法
PLoS One. 2014 Jan 29;9(1):e86717. doi: 10.1371/journal.pone.0086717. eCollection 2014.
4
Capture, release and culture of circulating tumor cells from pancreatic cancer patients using an enhanced mixing chip.使用增强混合芯片从胰腺癌患者中捕获、释放和培养循环肿瘤细胞。
Lab Chip. 2014 Jan 7;14(1):89-98. doi: 10.1039/c3lc51017d. Epub 2013 Nov 13.
5
An integrated microfluidic chip system for single-cell secretion profiling of rare circulating tumor cells.一种用于罕见循环肿瘤细胞单细胞分泌谱分析的集成微流控芯片系统。
Sci Rep. 2014 Dec 16;4:7499. doi: 10.1038/srep07499.
6
Clinical Microfluidic Chip Platform for the Isolation of Versatile Circulating Tumor Cells.临床微流控芯片平台用于多种循环肿瘤细胞的分离。
J Vis Exp. 2023 Oct 13(200). doi: 10.3791/64674.
7
[Recent advances in isolation and detection of circulating tumor cells with a microfluidic system].[微流控系统在循环肿瘤细胞分离与检测方面的最新进展]
Se Pu. 2022 Mar 8;40(3):213-223. doi: 10.3724/SP.J.1123.2021.07009.
8
EpCAM-independent capture of circulating tumor cells with a 'universal CTC-chip'.使用“通用循环肿瘤细胞芯片”对循环肿瘤细胞进行不依赖上皮细胞黏附分子(EpCAM)的捕获
Oncol Rep. 2017 Jan;37(1):77-82. doi: 10.3892/or.2016.5235. Epub 2016 Nov 8.
9
Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response.结合基于上皮细胞粘附分子和细胞表面波形蛋白的方法进行循环肿瘤细胞计数以监测乳腺癌治疗反应
Clin Chem. 2015 Jan;61(1):259-66. doi: 10.1373/clinchem.2014.228122. Epub 2014 Oct 21.
10
Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.循环肿瘤细胞通过上皮-间质转化逃避基于 EpCAM 的检测。
BMC Cancer. 2012 May 16;12:178. doi: 10.1186/1471-2407-12-178.

引用本文的文献

1
Microfluidics engineering towards personalized oncology-a review.面向个性化肿瘤学的微流控工程——综述
In Vitro Model. 2023 Jul 13;2(3-4):69-81. doi: 10.1007/s44164-023-00054-z. eCollection 2023 Aug.
2
Liquid Biopsy and Multidisciplinary Treatment for Esophageal Cancer.食管癌的液体活检与多学科治疗
Cancers (Basel). 2025 Jan 9;17(2):196. doi: 10.3390/cancers17020196.
3
Novel Isolating Approaches to Circulating Tumor Cell Enrichment Based on Microfluidics: A Review.基于微流控技术的循环肿瘤细胞富集新分离方法:综述
Micromachines (Basel). 2024 May 27;15(6):706. doi: 10.3390/mi15060706.
4
Circulating Tumour Cells: Detection and Application in Advanced Non-Small Cell Lung Cancer.循环肿瘤细胞:在晚期非小细胞肺癌中的检测与应用。
Int J Mol Sci. 2023 Nov 8;24(22):16085. doi: 10.3390/ijms242216085.
5
Evolution in Automatized Detection of Cells: Advances in Magnetic Microcytometers for Cancer Cells.细胞自动检测的发展:用于癌细胞的磁性微流控细胞仪的进展。
Adv Exp Med Biol. 2022;1379:413-444. doi: 10.1007/978-3-031-04039-9_17.
6
Analytical validation and initial clinical testing of quantitative microscopic evaluation for PD-L1 and HLA I expression on circulating tumor cells from patients with non-small cell lung cancer.非小细胞肺癌患者循环肿瘤细胞上PD-L1和HLA I表达的定量显微镜评估的分析验证和初步临床测试。
Biomark Res. 2022 Apr 25;10(1):26. doi: 10.1186/s40364-022-00370-8.
7
Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer-An Update.循环肿瘤细胞和循环肿瘤DNA在非小细胞肺癌中的临床应用——最新进展
Front Oncol. 2022 Mar 15;12:859152. doi: 10.3389/fonc.2022.859152. eCollection 2022.
8
Integration of Hierarchical Micro-/Nanostructures in a Microfluidic Chip for Efficient and Selective Isolation of Rare Tumor Cells.用于高效、选择性分离稀有肿瘤细胞的微流控芯片中的分级微/纳米结构集成
Micromachines (Basel). 2019 Oct 14;10(10):698. doi: 10.3390/mi10100698.
9
Recent advances in microfluidic methods in cancer liquid biopsy.癌症液体活检中微流控方法的最新进展。
Biomicrofluidics. 2019 Jul 23;13(4):041503. doi: 10.1063/1.5087690. eCollection 2019 Jul.
10
Is small smarter? Nanomaterial-based detection and elimination of circulating tumor cells: current knowledge and perspectives.小即是美?基于纳米材料的循环肿瘤细胞检测与清除:现有知识与展望。
Int J Nanomedicine. 2019 Jun 6;14:4187-4209. doi: 10.2147/IJN.S198319. eCollection 2019.

本文引用的文献

1
Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology.液体活检用于早期和晚期非小细胞肺癌患者循环肿瘤细胞鉴定:窥探肺癌生物学。
Phys Biol. 2012 Feb;9(1):016005. doi: 10.1088/1478-3967/9/1/016005. Epub 2012 Feb 3.
2
Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers.液体活检在转移性前列腺癌、胰腺癌和乳腺癌患者中的应用。
Phys Biol. 2012 Feb;9(1):016003. doi: 10.1088/1478-3975/9/1/016003. Epub 2012 Feb 3.
3
FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE™ platform.使用微流控CEE™平台分离的循环肿瘤细胞中基于荧光原位杂交技术的HER2状态测定
Cancer Genet. 2011 Nov;204(11):589-95. doi: 10.1016/j.cancergen.2011.10.011.
4
Circulating tumors cells as biomarkers: progress toward biomarker qualification.循环肿瘤细胞作为生物标志物:向生物标志物资格认证迈进。
Cancer J. 2011 Nov-Dec;17(6):438-50. doi: 10.1097/PPO.0b013e31823e69ac.
5
Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges.循环肿瘤细胞在乳腺癌中的检测系统、分子特征及未来挑战。
Clin Chem. 2011 Sep;57(9):1242-55. doi: 10.1373/clinchem.2011.165068. Epub 2011 Jul 22.
6
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment.循环肿瘤细胞作为一线系统治疗转移性乳腺癌患者的预后和预测标志物。
Breast Cancer Res. 2011 Jun 15;13(3):R67. doi: 10.1186/bcr2907.
7
Dynamic physical properties of dissociated tumor cells revealed by dielectrophoretic field-flow fractionation.介电泳场流分离技术揭示分离肿瘤细胞的动态物理特性。
Integr Biol (Camb). 2011 Aug;3(8):850-62. doi: 10.1039/c1ib00032b. Epub 2011 Jun 21.
8
Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers.来自晚期前列腺癌和乳腺癌患者的循环肿瘤细胞同时表达上皮和间充质标志物。
Mol Cancer Res. 2011 Aug;9(8):997-1007. doi: 10.1158/1541-7786.MCR-10-0490. Epub 2011 Jun 10.
9
A perspective on cancer cell metastasis.癌症细胞转移的观点。
Science. 2011 Mar 25;331(6024):1559-64. doi: 10.1126/science.1203543.
10
Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients.检测转移性乳腺癌患者中 EpCAM 阳性和阴性的循环肿瘤细胞。
Acta Oncol. 2011 Jun;50(5):700-10. doi: 10.3109/0284186X.2010.549151. Epub 2011 Jan 24.

一种使用微流控平台进行循环肿瘤细胞分离和计数的负选择方法。

A negative selection methodology using a microfluidic platform for the isolation and enumeration of circulating tumor cells.

机构信息

Department of Biomedical Engineering, University of Wisconsin - Madison, Madison, WI, USA.

出版信息

Methods. 2013 Dec 1;64(2):137-43. doi: 10.1016/j.ymeth.2013.05.027. Epub 2013 Jun 24.

DOI:10.1016/j.ymeth.2013.05.027
PMID:23806645
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3858973/
Abstract

Circulating tumor cells (CTCs) exist in the peripheral blood stream of metastatic cancer patients at rates of approximately 1 CTC per billion background cells. In order to capture and analyze this rare cell population, various techniques exist that range from antibody-based surface marker positive selection to methods that use physical properties of CTCs to negatively exclude background cells from a CTC population. However, methods to capture cells for functional downstream analyses are limited due to inaccessibility of the captured sample or labeling techniques that may be prohibitive to cell function. Here, we present a negative selection method that leverages a Microfluidic Cell Concentrator (MCC) to allow collection and analysis of this rare cell population without needing cell adhesion or other labeling techniques to keep the cells within the chamber. Because the MCC is designed to allow collection and analysis of non-adherent cell populations, multiple staining steps can be applied in parallel to a given CTC population without losing any of the population. The ability of the MCC for patient sample processing of CTCs for enumeration was demonstrated with five patient samples, revealing an average of 0.31 CTCs/mL. The technique was compared to a previously published method - the ELISPOT - that showed similar CTC levels among the five patient samples tested. Because the MCC method does not use positive selection, the method can be applied across a variety of tumor types with no changes to the process.

摘要

循环肿瘤细胞(CTCs)存在于转移性癌症患者的外周血液中,其比例约为每十亿背景细胞中有 1 个 CTC。为了捕获和分析这种稀有细胞群体,存在各种技术,从基于抗体的表面标志物阳性选择到利用 CTC 的物理特性将背景细胞从 CTC 群体中排除的方法。然而,由于捕获样本的不可及性或可能对细胞功能产生限制的标记技术,用于捕获细胞进行下游功能分析的方法受到限制。在这里,我们提出了一种阴性选择方法,该方法利用微流控细胞浓缩器(MCC)来允许收集和分析这种稀有细胞群体,而无需细胞粘附或其他标记技术来保持细胞在腔室内。由于 MCC 旨在允许收集和分析非粘附细胞群体,因此可以在给定的 CTC 群体中并行应用多个染色步骤,而不会丢失任何群体。MCC 用于对患者样本进行 CTC 计数的处理能力已通过五个患者样本进行了证明,结果显示平均每个样本中有 0.31 个 CTC/mL。该技术与之前发表的方法-ELISPOT-进行了比较,在测试的五个患者样本中显示出相似的 CTC 水平。由于 MCC 方法不使用阳性选择,因此该方法可以应用于各种肿瘤类型,而无需对该过程进行任何更改。